After COVID-19 outbreak in China in late 2019 and change to pandemic in early 2020, the
disease became a clinical threat to the whole world [1]. Urgent clinical guidance for intensive …

Introduction: Uncontrolled overproduction of inflammatory mediators is predominantly
observed in patients with severe COVID-19. The excessive immune response gives rise to …

Background: The new coronavirus outbreak quickly filled hospital beds and stunned the
world. Intensive care is required for 5% of patients, and the mortality rate for critically ill …

Introduction: Currently, the effect of hemoperfusion on outcome in severe COVID-19 patients
is still unknown. Therefore, we aimed to investigate the effects of early HA-330 …

Hemoperfusion is a method of blood filtering to remove toxins and inflammatory factors.
Cytokine storms and high levels of inflammatory factors play a role in the pathogenesis of …

The 2019 novel coronavirus (officially known as severe acute respiratory syndrome
coronavirus 2, SARS-CoV2) was first found in Wuhan, China. On February 11, 2020, the …

Introduction: Systematic inflammatory response occurred in some critically ill patients with
COVID-19. Cytokine reduction by hemadsorption is a mechanism of treatment. However …

We report a preliminary experience of adjuvant therapy with Hemoperfusion (HP) in patients
with Severe Acute Respiratory Syndrome-CoronaVirus 2 (SARS-CoV2) pneumonia …

Hemoperfusion (HP) was helpful to prevent the development and progression of acute
respiratory distress syndrome (ARDS), acute kidney injury (AKI), liver failure, and septic …

Abstract Background Coronavirus disease‐2019 (COVID‐19)‐related organ failure is partly
related to a sepsis‐like syndrome and extreme pro‐inflammatory cytokine release, named …